HK1198123A1 - The use of oligonucleotide chelate complexes - Google Patents

The use of oligonucleotide chelate complexes

Info

Publication number
HK1198123A1
HK1198123A1 HK14111304.2A HK14111304A HK1198123A1 HK 1198123 A1 HK1198123 A1 HK 1198123A1 HK 14111304 A HK14111304 A HK 14111304A HK 1198123 A1 HK1198123 A1 HK 1198123A1
Authority
HK
Hong Kong
Prior art keywords
chelate complexes
oligonucleotide chelate
oligonucleotide
complexes
chelate
Prior art date
Application number
HK14111304.2A
Other languages
English (en)
Chinese (zh)
Inventor
Andrew Vaillant
Michel Bazinet
Original Assignee
Replicor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45594559&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1198123(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Replicor Inc filed Critical Replicor Inc
Publication of HK1198123A1 publication Critical patent/HK1198123A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/04Chelating agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
HK14111304.2A 2010-08-20 2013-10-14 The use of oligonucleotide chelate complexes HK1198123A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37525710P 2010-08-20 2010-08-20

Publications (1)

Publication Number Publication Date
HK1198123A1 true HK1198123A1 (en) 2015-03-13

Family

ID=45594559

Family Applications (2)

Application Number Title Priority Date Filing Date
HK13111542.5A HK1184058A1 (zh) 2010-08-20 2013-10-14 寡核苷酸螯合物
HK14111304.2A HK1198123A1 (en) 2010-08-20 2013-10-14 The use of oligonucleotide chelate complexes

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK13111542.5A HK1184058A1 (zh) 2010-08-20 2013-10-14 寡核苷酸螯合物

Country Status (35)

Country Link
US (2) US8513211B2 (ru)
EP (1) EP2605794B1 (ru)
JP (1) JP5775581B2 (ru)
KR (3) KR20150039873A (ru)
CN (2) CN103768086B (ru)
AU (1) AU2011291401B2 (ru)
BR (1) BR112013003875B1 (ru)
CA (2) CA2806616C (ru)
CL (1) CL2013000445A1 (ru)
CO (1) CO6670525A2 (ru)
CR (1) CR20130069A (ru)
CU (1) CU20130022A7 (ru)
CY (1) CY1118207T1 (ru)
DK (1) DK2605794T3 (ru)
DO (1) DOP2013000041A (ru)
EA (1) EA026660B1 (ru)
EC (1) ECSP13012449A (ru)
ES (1) ES2598556T3 (ru)
GT (1) GT201300040A (ru)
HK (2) HK1184058A1 (ru)
HR (1) HRP20161333T1 (ru)
HU (1) HUE029521T2 (ru)
IL (1) IL224237A (ru)
LT (1) LT2605794T (ru)
MX (1) MX340294B (ru)
MY (1) MY160961A (ru)
NZ (1) NZ606364A (ru)
PL (1) PL2605794T3 (ru)
PT (1) PT2605794T (ru)
RS (1) RS55245B1 (ru)
SG (1) SG187165A1 (ru)
SI (1) SI2605794T1 (ru)
SM (1) SMT201600370B (ru)
WO (1) WO2012021985A1 (ru)
ZA (1) ZA201300497B (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ574807A (en) 2006-08-11 2011-01-28 Prosensa Technologies Bv Methods and means for treating dna repeat instability associated genetic disorders
PL2158316T3 (pl) 2007-05-11 2015-10-30 Adynxx Inc Ekspresja genowa oraz ból
CN101896186A (zh) 2007-10-26 2010-11-24 莱顿教学医院 对抗肌肉病症的方式和方法
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
EP4043039A1 (en) 2012-01-27 2022-08-17 BioMarin Technologies B.V. Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
EP4400169A2 (en) 2012-04-23 2024-07-17 Vico Therapeutics B.V. Rna modulating oligonucleotides with improved characteristics for the treatment of neuromuscular disorders
EP2846839B1 (en) 2012-05-10 2019-02-20 Adynxx, Inc. Formulations for the delivery of active ingredients
ES2873844T3 (es) * 2012-05-18 2021-11-04 Replicor Inc Composiciones de complejo de quelato de oligonucleótido y polipéptido y métodos
AR091065A1 (es) * 2012-05-18 2014-12-30 Replicor Inc Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviral
CA2877644A1 (en) * 2012-07-03 2014-01-09 Prosensa Technologies B.V. Oligonucleotide for the treatment of muscular dystrophy patients
KR102025679B1 (ko) * 2012-08-30 2019-09-26 레플리코르 인코포레이티드 B형 간염 및 d형 간염 감염증의 치료 방법
NZ727583A (en) 2014-07-10 2024-08-30 Replicor Inc Methods for the treatment of hepatitis b and hepatitis d virus infections
CA2957250A1 (en) 2014-08-15 2016-02-18 Adynxx, Inc. Oligonucleotide decoys for the treatment of pain
WO2016030863A1 (en) 2014-08-29 2016-03-03 Glaxosmithkline Intellectual Property Development Limited Compounds and methods for treating viral infections
RS60645B1 (sr) 2015-04-23 2020-09-30 Geron Corp Postupci za pripremu polinukleotida upotrebom kompozicija multivalentne katjonske soli
BR112021008539A2 (pt) * 2018-11-08 2021-08-03 Aligos Therapeutics, Inc. polímeros de oligonucleotídeos e métodos de inibição de transporte de antígeno s
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
US20230250125A1 (en) 2020-04-01 2023-08-10 Janssen Biopharma, Inc. Nucleic acid polymers
EP4247393A1 (en) * 2020-11-20 2023-09-27 Aligos Therapeutics, Inc. Conjugates of s-antigen transport inhibiting oligonucleotide polymers having enhanced liver targeting
TW202245809A (zh) 2020-12-18 2022-12-01 美商詹森藥物公司 用於治療b型肝炎病毒感染之組合療法
WO2022152869A1 (en) 2021-01-15 2022-07-21 Janssen Sciences Ireland Unlimited Company Use of oligonucleotides for individuals with hepatic impairment
CA3224600A1 (en) 2021-07-09 2023-01-12 Glaxosmithkline Intellectual Property (No.3) Limited Use of oligonucleotides for individuals with renal impairment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001514873A (ja) * 1997-08-20 2001-09-18 ソーマジェニックス インコーポレイテッド 結合特性が改善されたアンチセンスおよびアンチジーン治療薬並びにそれらの使用方法
JP3667047B2 (ja) * 1997-09-12 2005-07-06 キヤノン株式会社 人工核酸およびその製造方法、デオキシリボフラノース化合物、リボフラノース化合物およびこれらの製造方法
US6653467B1 (en) * 2000-04-26 2003-11-25 Jcr Pharmaceutical Co., Ltd. Medicament for treatment of Duchenne muscular dystrophy
JP4836366B2 (ja) * 2000-08-25 2011-12-14 雅文 松尾 デュシェンヌ型筋ジストロフィー治療剤
JP4783149B2 (ja) * 2003-09-02 2011-09-28 独立行政法人科学技術振興機構 金属錯体型核酸
US20060293510A1 (en) * 2003-09-08 2006-12-28 Japan Science And Technology Agency Metal complex type nucleic acid
JP2009500020A (ja) * 2005-07-01 2009-01-08 バイオヴェリス コーポレイション 核酸を検出、増幅および/また単離するための組成物および方法
WO2009065181A1 (en) * 2007-11-21 2009-05-28 Apollo Life Sciences Limited Nanostructures suitable for delivery of agents

Also Published As

Publication number Publication date
ZA201300497B (en) 2013-09-25
CY1118207T1 (el) 2017-06-28
ES2598556T3 (es) 2017-01-27
ECSP13012449A (es) 2013-04-30
CA2806616A1 (en) 2012-02-23
SI2605794T1 (sl) 2017-01-31
EP2605794A4 (en) 2014-07-02
NZ606364A (en) 2014-12-24
EA201300259A1 (ru) 2013-12-30
DK2605794T3 (en) 2016-10-24
DOP2013000041A (es) 2017-12-15
GT201300040A (es) 2014-09-02
KR20150039873A (ko) 2015-04-13
CO6670525A2 (es) 2013-05-15
CA2855690C (en) 2015-08-25
US20120046348A1 (en) 2012-02-23
PL2605794T3 (pl) 2017-01-31
CU20130022A7 (es) 2013-04-19
SMT201600370B (it) 2016-11-10
KR20150082685A (ko) 2015-07-15
US20130296410A1 (en) 2013-11-07
EA026660B1 (ru) 2017-05-31
CA2806616C (en) 2015-08-11
US8716259B2 (en) 2014-05-06
IL224237A (en) 2015-09-24
CA2855690A1 (en) 2012-02-23
US8513211B2 (en) 2013-08-20
HRP20161333T1 (hr) 2016-12-02
BR112013003875A2 (pt) 2018-03-13
CL2013000445A1 (es) 2013-11-22
RS55245B1 (sr) 2017-02-28
EP2605794A1 (en) 2013-06-26
HUE029521T2 (en) 2017-03-28
CN103052405B (zh) 2015-11-25
BR112013003875B1 (pt) 2021-10-05
AU2011291401B2 (en) 2014-11-27
MX340294B (es) 2016-07-04
JP5775581B2 (ja) 2015-09-09
MY160961A (en) 2017-03-31
WO2012021985A1 (en) 2012-02-23
CN103768086B (zh) 2015-10-14
CN103768086A (zh) 2014-05-07
EP2605794B1 (en) 2016-07-20
SG187165A1 (en) 2013-02-28
CR20130069A (es) 2013-09-20
MX2013001668A (es) 2013-07-22
JP2013536195A (ja) 2013-09-19
KR101606495B1 (ko) 2016-03-28
LT2605794T (lt) 2016-10-25
CN103052405A (zh) 2013-04-17
AU2011291401A1 (en) 2013-01-10
KR20130099067A (ko) 2013-09-05
HK1184058A1 (zh) 2014-01-17
PT2605794T (pt) 2016-10-25

Similar Documents

Publication Publication Date Title
HK1198123A1 (en) The use of oligonucleotide chelate complexes
IL221416A0 (en) Alpha-emititng complexes
IL226299A (en) Oligonucleotides that stimulate the immune system
GB2493683B (en) Time-key hopping
PT2585216T (pt) Complexos de п-alilpaládio e п-alilníquel para utilização como catalisadores em reações de acoplamento de carbono-carbono e carbono-azoto
EP2548959A4 (en) FLORIGENIC ACTIVATOR COMPLEX
ZA201206793B (en) Nucleic acid complexes
HK1173368A1 (en) Pigmentation-preventing or-ameliorating agent
GB201104522D0 (en) Complexes
EP2619274A4 (en) ANTI-KOGATION AGENTS
GB201010960D0 (en) Complex
EP2640832A4 (en) NEW ETHIOLOGICAL AGENT
GB201005227D0 (en) 4-Pin pegbar
GB201001670D0 (en) Use
GB201000631D0 (en) New use
GB201009537D0 (en) Clasp
GB201014868D0 (en) Concept 39
GB201014860D0 (en) Concept 35
GB201014870D0 (en) Concept 43
GB201014869D0 (en) Concept 40
GB201014872D0 (en) Concept 46
GB201014867D0 (en) Concept 38
GB201014866D0 (en) Concept 37
GB201014864D0 (en) Concept 36
GB201014871D0 (en) Concept 44